Array BioPharma

The Company’s wholly owned clinical stage drugs include Filanesib in Phase II clinical trials, is indicated for Kinesin spindle protein (KSP), inhibitor for MM; ARRY-797 in Phase II clinical trials, indicated for p38 inhibitor for Lamin A/C-related dilated cardiomyopathy (LMNA-DCM); ARRY-502 in Phase II clinical trials, indicated for CRTh2 antagonist for asthma, and ARRY-614 in Phase I clinical trials, is indicated for p38/Tie2 dual inhibitor for myelodysplastic syndromes (MDS). In addition, the Company has 11 ongoing partner-funded clinical programs, including two MEK inhibitors, which are both in Phase III clinical trials, binimetinib with Novartis and selumetinib with AstraZeneca.

Boulder, US
Size (employees)
177 (est)+14%
Array BioPharma was founded in 1998 and is headquartered in Boulder, US

Array BioPharma Office Locations

Array BioPharma has offices in Boulder, Cambridge, Morrisville, Houston and in 4 other locations
Boulder, US
Charlotte, US
Phoenix, US
Detroit, US
New York, US
Houston, US
Morrisville, US
Cambridge, US

Array BioPharma Metrics

Array BioPharma Summary

Market capitalization

$1.6 b

Closing share price

Array BioPharma's current market capitalization is $1.6 b.

Array BioPharma Financials

Array BioPharma's revenue is $137.9 m in FY, 2016 which is a 165.6% increase from the previous period.
FY, 2014FY, 2015FY, 2016


$42.1 m$51.9 m$137.9 m

Revenue growth, %


Gross profit

($3.9 m)$7.5 m$114.7 m

Operating expense total

$117.7 m$130.3 m$220.1 m


($75.6 m)$3.3 m($82.2 m)

Net Income

($85.3 m)$9.4 m($92.8 m)

Operating cash flow

$7.9 m($12.9 m)$907 k

Array BioPharma Market Value History

Array BioPharma Company Life

You may also be interested in